SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > All Ingredients News

Merck KGaA biopharma division to make small molecule drugs in China

29-Aug-2014 - Biopharmaceutical firm Merck Serono will make small molecule drugs at the new plant it is building in China according to a company spokeswoman, who told us the firm will supply both local and international markets.

GSK: GM yeast breakthrough won't kill off poppy-based opium

28-Aug-2014 - Poppies will continue to be the main source of industrial opiates long-term according to GSK, despite a recent breakthrough in efforts to produce it in GM yeast.

DEA approves manufacture of GHB at Patheon Cincinnati plant

26-Aug-2014 - Patheon has received approval from the DEA to bulk manufacture the schedule I product Gamma Hydroxybutyric Acid (GHB) from its facility in Cincinnati, Ohio.

EMD Millipore to supply Samsung's Yervoy plant in 10-year deal

26-Aug-2014 - EMD Millipore has been contracted to supply raw materials to the Samsung Biologics plant where ingredients for BM-S’ anticancer monoclonal antibody Yervoy (ipilimumab) are made.

EFPIA, EGA take issue with EMA’s guidance on stability data for APIs

25-Aug-2014 - EFPIA (European Federation of Pharmaceutical Industries and Associations) and EGA (European Generics Association) have released comments suggesting specific changes to the EMA’s draft guidance on stability data for manufacturing changes.

Claris gets MHRA OK for injectables plant

21-Aug-2014 - Indian manufacturer Claris Lifesciences has had its injectable drug manufacturing facility in Ahmedabad approved by the UK MHRA.

Macfarlan Smith fined $12,000 after accident at API plant

21-Aug-2014 - Opiate API manufacturer Macfarlan Smith has been fined £12,000 for failing to ensure the safety of an employee injured at its plant in Scotland in 2011.

US FDA 'stamp of approval' testament to WuXi's growth in APIs

19-Aug-2014 - WuXiPharmaTech has received US FDA approval to manufacture an API for a commercial drug from a plant in Shanghai.

Recipharm to buy Corvette to drive Italian growth and boost freeze drying clout

19-Aug-2014 - Recipharm will buy Corvette Pharmaceutical Services Group from private equity owners LBO Italia Investimenti to add much needed lyophilisation capacity and increase access to the Italian market.

US mulls Federal Trade Zone status for Neolpharma Puerto Rico plant

18-Aug-2014 - US authorities are reviewing a Neolpharma request for tax breaks for APIs imported to a former Pfizer-owned plant it operates in Puerto Rico.

API sales down 81% as Ranbaxy feels fallout from US import alerts

14-Aug-2014 - Ranbaxy has reported a 14% drop year-on-year of overseas revenues attributed in part to the voluntary suspension of shipments from its Toansa and Dewas facilities API facilities.

Sanofi begins distribution of semi-synthetic antimalarials in Africa

14-Aug-2014 - Over the next few months Sanofi and non-profit PATH are delivering the first large-scale batches of an artemisinin-based combination therapy to five African countries, which will for the first time be manufactured with semi-synthetic artesunate.

Daiichi sells API plant and outlines business rejig

11-Aug-2014 - Daiichi Sankyo has agreed to sell a Japanese API plant to Alfresa Pharma as part of a wider reorganisation of its business.

News in brief

Ashland expands HPC production at VA plant

11-Aug-2014 - Fine chemicals manufacturer Ashland has laid down plans to expand a Klucel hydroxypropylcellulose (HPC) plant in Virginia to meet growing pharma demand.

THC may reduce tumor size? mouse study investigates

07-Aug-2014 - A previously unknown signaling platform may be responsible for the success of the main psychoactive ingredient in cannabis in reducing tumour size, which also may lead to the development of a synthetic THC equivalent, scientists say.

NIH toxicology contract renewed for MRIGlobal despite tightening budget

06-Aug-2014 - The tightening federal budget is increasing competition between research institutes and academia when it comes to preclinical toxicology testing, according to MRIGlobal.

News in brief

US, foreign API facilities to see FDA fees spike in 2015

05-Aug-2014 - US and foreign API facilities will see their annual US FDA facility fees rise more than $5,000, while their FDF (fixed-dose form) counterparts will see their fees rise by more than $20,000.

China's GMP drive will reduce API competition, says ScinoPharm

04-Aug-2014 - China has tightened its GMP requirements and compliant API suppliers will benefit from a reduction in competition, according to ScinoPharm.

Ireland looks to switch 12 APIs from prescription to OTC medicines

04-Aug-2014 - The Health Products Regulatory Authority (HPRA) of Ireland has published a list of 12 active substances contained in medicines that could potentially be switched from prescription-only to over the counter sale.  

Chinese firm imported misbranded API into US, says FDA warning letter

30-Jul-2014 - Zhejiang Jiuzhou Pharmaceutical has received an FDA warning letter after shipping a misbranded active pharmaceutical ingredient to the US.

Ipca halts API shipments to US following 483 at Indian plant

24-Jul-2014 - Ipca Laboratories has halted shipments to the US of active pharmaceutical ingredients (APIs) made from a facility in India following a US FDA inspection.

Onyx contracted for API R&D and manufacturing by UK cancer charity

23-Jul-2014 - Onyx Scientific has been contracted to develop and manufacture APIs for clinical trials by charitable group Cancer Research UK.

ADHD API sales up, specialty opiates down at Johnson Matthey in Q1

23-Jul-2014 - Johnson Matthey’s API business had a mixed fiscal Q1 with gains made in ADHD ingredients and bulk opiates being accompanied by a decline in revenue from specialty opiates.

European Pharmacopoeia plans revisions of elemental impurities guideline

23-Jul-2014 - As the International Conference on Harmonisation (ICH) signs off on a new tripartite guideline related to elemental impurities, the European Pharmacopoeia Commission will revise its texts to ensure consistency. 

New nanotech excipient offers cheaper solubility option say scientists

22-Jul-2014 - Scientists in Sweden have developed a magnesium carbonate-based excipient they claim is a low-cost nanotech alternative to silica for drugmakers struggling to formulate insoluble APIs.

Spotlight

SCM's woes part of UK-wide aseptic slowdown, says ex-owner

SCM's woes part of UK-wide aseptic slowdown, says ex-owner

GMP failures at an aseptic plant owned by SCM Pharma are part of a wider industry trend...

Boehringer aims to cut German costs 15% as H1 sales fall

Boehringer Ingelheim aims to cut German costs 15% as revenues drop

German jobs are safe despite a programme that will cut the cost of operations by 15%, Boehringer...

WHO: Data from use of unapproved Ebola drugs should be shared

WHO: Data from use of unapproved Ebola drugs should be shared

Efficacy and safety data from use of unapproved Ebola virus treatments should be shared according to an...

THC may reduce tumor size? mouse study investigates

THC may reduce tumor size? mouse study investigates

A previously unknown signaling platform may be responsible for the success of the main psychoactive ingredient in...

India’s CDSCO outlines procedures for state manufacturer inspections

India’s CDSCO outlines procedures for state inspections of manufacturers

In order to ensure uniformity on the state and federal levels, India’s CDSCO (Central Drugs Standard Control...

Roche re-enters RNAi space with $250m Santaris acquisition

Roche re-enters gene silencing space with $250m LNA acquisition

Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its...

Key Industry Events

 

Access all events listing

Our events, Events from partners...